Alzamend Neuro, Inc. — Form 8-K Summary
Event date: September 29, 2026. This current report announces a scientific presentation; it does not report a financial quarter or year.
Business context
Dr. Ovidiu C. Andronesi, principal investigator on the company’s Phase 1/2A clinical trial, was scheduled to present at the International Society for MR Radiographers & Technologists (ISMRT) Conference. The presentation is furnished as Exhibit 99.1.
Financial results and liquidity
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial performance figures.
Changes, outlook, and risks
No financial or operational changes, guidance, or specific clinical results are described in the supplied filing text. The company’s standard forward-looking-statement caution notes that statements involve risks and uncertainties and actual results may differ materially. The presentation is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act, subject to the filing’s stated terms.
Investor verification points
- Review Exhibit 99.1 for the presentation’s actual content, including any clinical data, qualifications, or forward-looking statements.
- Consult the company’s other filings for current financial condition, cash runway, and clinical-trial updates; this 8-K does not provide those details.